© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

ANSWERING THE NEED WITH

PREDICTIVE MODELS

Helomics believes it has a solution to Pharma’s need for multi-omic data by leveraging two unique assets;

• A clinically validated patient-derived (PDx) tumor profiling platform (TruTumor™) that can generate drug response profiles and other multi-omic data. 

• Data on the drug response profiles of over 150,000 tumors across 137 cancer types tested using the PDx platform in over 10+ years of clinical testing

Helomics is leveraging these assets, using the proven power of AI to build multi-omic predictive models of tumor drug response.

THE UNMET NEED IN PRECISION MEDICINE

Pharma has invested heavily in genomics and “big data” to understand each patient’s genome to target therapies, yet success rates for targeted therapies are low and uptake in clinical practice is patchy. There is a growing realization now that “just genomics” is not enough and there is a clear unmet need for a multi-omic approach, which may offer a greater chance of success, but such data is difficult to access quickly. Few comprehensive, multi-omic datasets exist and it is time-consuming to initiate prospective data collection especially in cancer.